Menu Close

1900 Wealth Management LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

view original post

1900 Wealth Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 9.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 8,898 shares of the company’s stock after acquiring an additional 798 shares during the period. 1900 Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,577,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. State Street Corp lifted its position in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares during the period. Geode Capital Management LLC boosted its holdings in Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $4,172,929,000. Finally, Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 5.8% in the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after buying an additional 948,306 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 0.6 %

Shares of Johnson & Johnson stock opened at $170.71 on Thursday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The business has a 50 day moving average price of $176.48 and a 200 day moving average price of $174.34. The company has a market capitalization of $449.21 billion, a P/E ratio of 23.01, a P/E/G ratio of 3.41 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period in the previous year, the firm posted $2.48 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.2 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.65%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. SVB Leerink cut their price objective on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating on the stock. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $191.13.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.